Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05989724 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
A Phase 1 study of Breast Cancer and Colorectal Cancer, sponsored by Qurgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 5
- Study locations
NCT05989724: Recruiting Phase 1 study of Breast Cancer and Colorectal Cancer, sponsored by Qurgen.
NCT05989724 is a Phase 1 study of Breast Cancer and Colorectal Cancer that is actively recruiting participants, run by Qurgen. The registered enrollment target is 150 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05989724, a Phase 1 study of Breast Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by Qurgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 5
- Study locations
Study Summary
This proposed Phase I clinical trial of SON-DP is an FIH, open-label, Phase Ia/Ib dose escalation and expansion study to evaluate the safety, tolerability, PK, and PD of SON-DP in participants with relapsed/refractory/intolerant to standard of care therapies, for advanced/ metastatic solid tumors.
Conditions Studied
Interventions
- DRUG SON-DP
Study Locations (5)
Arizona
- Banner MD Anderson Cancer Center (BMDACC) - Gilbert
Michigan
- Henry Ford Health System - Detroit
North Carolina
- Carolina BioOncology Institute - Huntersville
Oklahoma
- Stephenson Cancer Center, University of Oklahoma - Oklahoma City
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2023-09-19 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
What NCT05989724 shows while recruiting
NCT05989724 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower).
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which SON-DP is the first listed.
NCT05989724 lists 5 locations in 5 states (Arizona, Michigan, North Carolina).
Frequently Asked Questions
What is clinical trial NCT05989724 about?
NCT05989724 is a clinical study titled "A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors". This proposed Phase I clinical trial of SON-DP is an FIH, open-label, Phase Ia/Ib dose escalation and expansion study to evaluate the safety, tolerability, PK, and PD of SON-DP in participants with relapsed/refractory/intolerant to standard of care therapies, for advanced/ metastatic solid tumors.
What is the current status of trial NCT05989724?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2023-09-19. Estimated completion is 2026-03.
What conditions does trial NCT05989724 study?
This clinical trial studies the following conditions: Breast Cancer, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer, Solid Tumor.
What interventions are being tested in trial NCT05989724?
The interventions under investigation include: SON-DP (DRUG).
Who is sponsoring clinical trial NCT05989724?
This trial is sponsored by Qurgen, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05989724 being conducted?
This trial has 5 study locations across Arizona, Michigan, North Carolina, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05989724's enrollment target sits among peer trials
150 444th of 1224 higher than 772 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI